Preventing the Next Heart Attack

We’ve got your heart covered


It takes only 4 minutes to prevent the next heart attack*

CORA is a short exam that indicates a patient’s risk-level for having CAD. CORA has the potential to save the lives of millions of patients worldwide, while simultaneously decreasing health care-related costs.


Product not cleared yet by the FDA. Not available for sale in the US.



Validated in clinical study

Easy to Use

Easy to Use

Can be performed by any medical staff personnel in any setting



Zero cost per exam



4-minute exam

Cost Effective

Cost Effective

Can save millions of dollars on medical expenses



Non-invasive, no radiation

Early Detection Tools Fall Short

Currently, physicians have limited front-line diagnostic tools for the early detection of Coronary Artery Disease (CAD) - the cause of heart attacks.

Results chart

CAD in Numbers

#1 Cause of death globally – 9M deaths each year
16 million people worldwide have a heart attack each year
Every 30 seconds someone in the US has a heart attack
800,000 Heart attacks annually in the US
Men over the age of 40 have 50% lifetime risk of developing CAD
20% of all hospitalization in the US are the direct result of CAD
7% of the US adult population suffer from CAD
CAD accounts for 1/3 of US deaths in patients over the age of 35


Any patient. Anytime. Anywhere.

AccuLine’s technology is based on the detection of 2 novel bio-signals in combination with AI-powered signal processing and proprietary augmented waveform display.


2 Novel Bio-Signals

  • Voltage Spread – inter-cycle variability of the voltage

  • VCG – 3D image of the heart’s electrical activity


Augmented Data Display

  • Proprietary novel data display technology


Advanced Signal Processing

  • Novel analysis of electric signals

  • Improved filtering algorithm

Clinical Results

Significant difference between patient with and without significant CAD



AccuLine was founded with the vision to save the lives of millions of people worldwide by preventing the next heart attack. AccuLine is developing CORA – an accurate, non-invasive, swift, and cost-effective examination for early detection of CAD, designed to replace the inaccurate, time-consuming, and labor-intensive stress test examinations.

AccuLine has received a grant from the Israeli Innovation Authority, with investors including Maccabi Healthcare Services. It is a portfolio company of eHealth Ventures, Israel’s leading digital health-tech VC, founded by Maccabi Healthcare Services and backed by Amgen, Medison Ventures, and SCI (Shanghai Creation Investment).

eHealth Ventures
Israel Innovation Authority


Led by experts to revolutionize the future of
ischemic heart disease managment

Moshe Barel
CEO & Co-Founder


Moshe has more than 15 years of experience in the medical device industry, having taken leadership roles within start-up companies and global corporates. Before joining AccuLine, Moshe served as CEO of Intratech Medical, where he continues to serve as an Executive Chairman today. Prior to that, Moshe served as  CEO at Sanolla, VP of Strategy at NovaSight, and business unit director at Lumenis and Johnson & Johnson.

Moshe holds a BA in Economics AND Business Administration and an MSc in Business Administration – both from Tel-Aviv university. LinkedIn

Prof. Aharon Frimerman
CMO & Co-Founder


Aharon Frimerman, M.D, is a cardiologist and head of the catheterization laboratory unit at Hillel-Yaffe Medical Center, Israel, as well as a Professor of Cardiology at the faculty of medicine of the Technion, the Israeli Institute of Technology. Prof.  Frimerman serves as a member of the editorial board at the journal of the Israel Heart Society, reviewer at the Journal of Interventional Cardiology and member of the interventional cardiology devices committee for the Israeli ministry of health. He has won several awards from the Israeli Heart Society, the Israeli ministry of health, Technion’s faculty of medicine, and Hillel-Yaffe medical center for excellence in research and in teaching. Prof. Frimerman has published dozens of scientific papers and has 9 patents under his name. Prof. Frimerman also served as an advisor to Boston Scientific, Siemens, RDC Medical, Angioslide, Sync-Rx, Elcam Medical, and Naiot Technological Center.

Benny Shani
CTO & Co-Founder


Benny is a veteran R&D leader with almost 40 years of experience in executive roles within numerous hi-tech organizations, in various fields.  Benny started his career at the Israel Military Industries in the rocket division’s computer center. Following that Beni joined Tecnomatix as product manager, where he developed 3D computer aided process planning later implemented by several large car manufacturers as well as aerospace, energy, and industrial companies. After that, Benny served as VP of Technologies at PixelMultimedia. Following that, Benny was the co-founder and VP of R&D at New Media Communications, which was acquired by Harmonic Data Systems, where Benny was appointed as CTO.

Benny has a BSc (cum laude) and an MSc in mechanical engineering, both from the Technion, the Israeli Institute of Technology, and he holds 4 patents under his name. LinkedIn

Prof. Shai Revzen
CSO & Co-Founder


Shai Revzen is an Associate Professor in the departments of Electrical Engineering and Computer Science at the University of Michigan, Ann Arbor, and a founding member of the Michigan Robotics Institute.  Prof. Revzen holds a PhD in biomechanics from the University of California, Berkeley, an MSc in computer science from the Hebrew University in Jerusalem and did his post-doctoral in University of Pennsylvania. He heads the BIRDS Lab, which focuses on the crucial role of mechanics in robot motion. Prof. Revzen has more than 100 scientific publications in top engineering, biology and applied mathematics journals, and several registered patents. LinkedIn

Scientific Advisory Board


Dr. Amir Lerman


Amir Lerman, M.D. is an endowed named Barbara Lips Professor of Medicine and a Consultant in the Department of Cardiovascular Medicine at the Mayo Clinic School of Medicine.   Dr. Lerman serves as an Associate Chair of the Department of Cardiovascular Medicine and the Director of the Cardiovascular Research Center at Mayo Clinic, and the Medical Director of the Chest Pain and Coronary Physiology Clinic. Dr. Lerman serves as the Medical Director of Mayo-Israeli startup company initiative and on the faculty of the Merage Institute for Medical Innovation.  Dr. Lerman graduated from the Technion School of Medicine, Israel and completed his training inInternal Medicine, Cardiovascular Medicine and Invasive Cardiology at Mayo Clinic. Dr. Leman’s interest is coronaryphysiology and imaging, regenerative medicine, innovative technologies, and digital health. Dr. Lerman has published more than 630 manuscripts, book chapters, and reviews.  The NIH, AHA, and several foundations support his research.

Dr. Roxana Mehran


Roxana Mehran, M.D is Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at Mount Sinai School of Medicine. Dr. Mehran is internationally recognized for her experience and expertise in working with regulatory agencies to conduct clinical trials.

Dr. Mehran served as Course Co-Director of the annual TCT for the last 13 years.  Dr. Mehran serves on editorial board of multiple peer reviewed journals, including Journal of the American College of Cardiology, Circulation, and Circulation Research. She currently serves on the board of trustees of SCAI, as a member of the Program Committee for the American Heart Association Scientific Sessions and is also the Chief Scientific Officer of the Clinical Trials Center at the Cardiovascular Research Foundation (CRF). Dr. Mehran has published more than 1,300 scientific papers and has been cited over 200,000 times.


Preventing the Next Heart Attack

2 Rafael-Eitan St.
Petach-Tikva, 4906508



    Skip to content